Drug Trial Radar · NCT04082429
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
156
Actual
Start
Nov 13, 2019
Primary completion
Jul 12, 2022
Study completion Feb 21, 2028
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Sep 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bleeds (on-demand) will be placed in one of two groups. In one group participants will get study medicine from the start of the study. In the other group participants will continue with their normal medicine and get study medicine after 6 months. Which treatment the participant gets is decided by chance. Participants who usually take medicine to prevent bleeds (prophylaxis treatment) or who are already being treated with concizumab (study medicine) will receive the study medicine from the start of the study. Participants will have to inject themselves with the study medicine 1 time every day under the skin. This can be done at home. The study doctor will hand out the medicine in the form of a pen-injector. The pen-injector will contain the study medicine. The study will last for up to 8 years. The length of time the participant will be in the study depends on when they agreed to take part and when the medicine is available for purchase in their country (or 31 December 2027 at the latest). The time between visits will be approximately 4 weeks for the first 6 to 12 months depending on the group participants are in, and approximately 8 weeks for the rest of the study. If the participant attends extra visits due to the prescription medicine not being available for purchase in their country, these will be 14 weeks apart. Participants will be asked to record information in an electronic diary during the study and may also be asked to wear an activity tracker.
Conditions
- Haemophilia A Without Inhibitors
- Haemophilia B Without Inhibitors
Interventions
ConcizumabDrug
When patients are randomised/allocated to concizumab prophylaxis, they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week (Wk) 0) (arm 2, 3 and 4) or visit 9a (Wk 24) (arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (Wk 6) or 9a.3 (Wk 30) and will be based on the concizumab exposure level measured at the previous visit 4a (Wk 6) or 9a.2 (Wk 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual replacement therapy until visit 9a (week 24; end of main part). In the extension part, patients in arm 1 will receive daily concizumab subcutaneous injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Haemophilia A Participants Without Inhibitors: Rate of Treated Spontaneous and Traumatic Bleeding EpisodesTime frame: On demand (arm 1): From week 0 up until start of concizumab treatment (week 24); Concizumab (arm 2): From week 0 up until the confirmatory analyses cut-off
- Haemophilia B Participants Without Inhibitors: Rate of Treated Spontaneous and Traumatic Bleeding EpisodesTime frame: On demand (arm 1): From week 0 up until start of concizumab treatment (week 24); Concizumab (arm 2): From week 0 up until the confirmatory analyses cut-off
Locations
113 sites in 33 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles - Endocrinology
Los Angeles, California
Center for Inherited Blood Disorders
Orange, California
Center for Blood Disorders Augusta University
Augusta, Georgia
Indiana Hemophilia-Thromb Ctr
Indianapolis, Indiana
University of Iowa_Iowa City
Iowa City, Iowa
Children's Hospital of Michigan
Detroit, Michigan
Michigan State University
Lansing, Michigan
Novant Hlth Vasc Ins Charlotte
Charlotte, North Carolina
M.S. Hershey Medical Center
Hershey, Pennsylvania
Vanderbilt University Medical Center_Nashville_0
Nashville, Tennessee
University of Texas San Antonio
San Antonio, Texas
Versiti, CCBD
Milwaukee, Wisconsin
Haematology and Blood Bank Department
Algiers, Algeria
CHU Constantine BEN BADIS/ Hematology department
Constantine, Algeria
The Alfred
Melbourne, Victoria, Australia
Royal Children's Hospital
Parkville, Victoria, Australia
The Royal Children's Hospital
Parkville, Victoria, Australia
Fiona Stanley Hospital - Haemophilia and Haemostasis Centre
Murdoch, Western Australia, Australia
University Clinical Center of Republic Srpska (205)
Banja Luka, Bosnia and Herzegovina
UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
Sofia, Bulgaria
UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
Varna, Bulgaria
Eastern Health Authority
St. John's, Newfoundland and Labrador, Canada
Hamltn Hth Sci/McMstr Child Hosp
Hamilton, Ontario, Canada
KBC Zagreb_Hematology
Zagreb, Croatia
Copenhagen Center for Heamatology
Copenhagen, Denmark
North Estonia Medical Centre Foundation
Tallinn, Estonia
Centre Hospitalier Regional Et Universitaire de Brest-Hopital de La Cavale Blanche
Brest, France
CHU de Caen - Côte de Nacre
Caen, France
Hopital de Bicetre
Le Kremlin-Bicêtre, France
Centre Hospitalier Universitaire de Nantes-Hopital Hotel-Dieu
Nantes, France
Hôpital Pontchaillou
Rennes, France
Centre Hospitalier Universitaire de Saint Etienne-Hopital Nord
Saint-Priest-en-Jarez, France
Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie
Bonn, Germany
Universität des Saarlandes - Hämostaseologie und Transfusionsmedizin
Homburg, Germany
MH Eü. Központ -Orszagos Haemophilia Kozpont
Budapest, Hungary
St. John's Medical college and Hospital
Bangalore, Karnataka, India
Sahyadri Speciality Hospital
Pune, Maharashtra, India
Sahyadri Super Speciality Hospital
Pune, Maharashtra, India
J K Lon Hospital
Jaipur, Rajasthan, India
CMCV
Ranipet, Tamil Nadu, India
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.